Altogether, the above data substantiated the heterogenous impacts of FOSB on the malignant biological behaviors and cisplatin sensitivity in a specific transcriptional target-dependent manner in NSCLC cells bearing different genetic backgrounds of TP53. The gene discussed is TP53; the disease is non-small cell lung carcinoma.